InvestorsHub Logo
icon url

LongGame

05/30/18 5:07 PM

#71181 RE: Medicus30 #71180

Not a good article for us at all
icon url

ki2002rom

05/30/18 5:13 PM

#71184 RE: Medicus30 #71180

Biased, incomplete, misrepresented facts, false information. I wonder if it's the same author before..... will have to check.... who was 'anonymous' until SA and he was called out and now included in the investigation that's ongoing, encapsulating the past few months. The author who by the way then tried to come back and cover his behind with a name and distant website. Needless to say a nuisance distraction that will soon evaporate with the train of news coming.
icon url

cantwaittoretire

05/30/18 5:33 PM

#71187 RE: Medicus30 #71180

I just skimmed it, but from what I saw, I will say this: For one, it's one person's opinion, so take that for what it's worth. Also, he only talks about the Oracle deal. I didn't see a mention of Marketo, dr2, the other marketing companies, or NotifiEDU, NotifiHealth, or anything else. Of course, if you think the only thing nFusz has going for it is being an add-on to Netsuite, then you wouldn't think it was that great, but there is a whole lot more to nFusz and this is still just the beginning. It didn't change my mind one bit.
icon url

jcoxs

05/30/18 6:04 PM

#71190 RE: Medicus30 #71180

Succinctly and successfully articulates why FUSZ is so fundamentally overvalued. Without significant revenues over the next two quarters to offset operating expenses, the dilution will push OS to near maximum AS, which means increase or reverse split. Plain and simple!
icon url

trding

05/30/18 6:26 PM

#71201 RE: Medicus30 #71180


what is disappointing is the Sales, General, and Administrative (SG&A) expenses. They increased from $617,537 in Q1 2017 to $5,269,574 for Q1 2018. Not only is that an increase of 750% year over year, it is more than the 2017 total SG&A of $4,327,529.



They clearly don't understand anything about those numbers with the above quote.




Taking into consideration the recent form D's filed by the company for additional unregistered sales of securities, there is about 154M shares outstanding, with only 200M authorized. At this rate, the company will max out the share count in the next couple of quarters.



The company has enough cash to last 1 year. So this is wrong also.



Interestingly enough, the company has chosen to pay off lower cost, longer term convertible notes before addressing higher cost notes, to the extent that one is now (or was as of the quarterly filing) in default.



I guess they didn't pick up on Rory owns the remaining debt and this is why the other debt was paid.



The Potential for Up-listing



Waited a lot of time explaining a lot of details. Remove all that and say the one requirement needed is to get share price up to whatever the listing requires, it is 58c... its got a long way to go and my guess is it will take an impressive jump in q2 or q3 revs to get there.

To meet the per share price requirement, the company simply needs to implement a reverse split.



Rory has said this is not happening. If the share price does not get there organically, the uplist will not happen this year.


With the share price falling from $3 to .58 one should expect articles of this nature though.

icon url

Ziptrader0

05/30/18 7:01 PM

#71210 RE: Medicus30 #71180

You asked for thoughts on the article. In my opinion it was poorly written and more speculative than the stock it was discussing nFusz. I only saw a thumbs up button; if there was one for thumbs down I would have hit it.I don't think it will harm the share price any more than a positive article helps it.It does give you a sense of how SA articles can vary enormously in their quality. Bankruptcy? Cough. Cough. Two new big enterprise agreements about to be announced. Ultra long Fusz. Hang in there for what is coming, in my estimation. The nonsense will end, hopefully soon.